Incidence of blindness in open-angle glaucoma in Sweden: a long-term follow-up study
Abstract
Background: Open-angle glaucoma (OAG) is a leading cause of irreversible blindness. There are no prospective studies on the risk of developing blindness in both eyes in individuals with definite OAG.
Methods: A total of 354 patients with newly diagnosed OAG, who had participated in four studies conducted at the Eye Department in Tierp, Sweden, from 1979 to 2006, were included in the investigation. Using the World Health Organization’s criteria for blindness, medical records, glaucoma case records, and visual fields were reviewed to identify patients who developed bilateral blindness. Incidence proportions and incidence rates were estimated. To assess potential risk factors for blindness, standardised morbidity ratios (SMRs) were calculated. The effects of age and sex were also analysed using Cox proportional hazard models.
Results: By the end of the study in August 2023, 33 cases of blindness caused by OAG had been found, corresponding to an incidence proportion of 9.3% (95% confidence interval [CI]: 6.5–12.8%). Within the first 20 years, 29 cases were detected, yielding a proportion of 8.2% (95% CI: 5.5–11.6%). The incidence rate was estimated to be 8.6 per 1,000 person-years (95% CI: 5.9–12.6 per 1,000 person-years). Glaucoma-related blindness was associated with male sex (SMR 2.33; 95% CI: 1.13–4.80). The hazard ratio was doubled for every 5 year of increasing age (2.21; 95% CI: 1.60–3.05).
Conclusion: In this study of blindness in newly diagnosed OAG in a Swedish population, approximately one in 10 patients progressed to bilateral blindness caused by the disease. Old age and male sex were identified as significant risk factors.
Downloads
References
2. Broman AT, Quigley HA, West SK, Katz J, Munoz B, Bandeen-Roche K, et al. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008;49:66–76. doi: 10.1167/iovs.07-0866
3. George R, Panda S, Vijaya L. Blindness in glaucoma: primary open-angle glaucoma versus primary angle-closure glaucoma – a meta-analysis. Eye. 2022;36:2099–105. doi: 10.1038/s41433-021-01802-9
4. Ekström C. Risk factors for incident open-angle glaucoma: a population-based 20-year follow-up study. Acta Ophthalmol. 2012;90:316–21. doi: 10.1111/j.1755-3768.2010.01943.x
5. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105:2099–104. doi: 10.1016/S0161-6420(98)91133-2
6. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology. 2003;110:726–33. doi: 10.1016/S0161-6420(02)01974-7
7. Forsman E, Kivelä T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma. 2007;16:313–19. doi: 10.1097/IJG.0b013e318033500f
8. Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol. 2013;156:724–30. doi: 10.1016/j.ajo.2013.05.027
9. Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology. 2014;121:134–41. doi: 10.1016/j.ophtha.2013.09.003
10. Ang GS, Eke T. Lifetime visual prognosis for patients with primary open-angle glaucoma. Eye. 2007;21:604–8. doi: 10.1038/sj.eye.6702284
11. Goh YW, Ang GS, Azuara-Blanco A. Lifetime visual prognosis of patients with glaucoma. Clin Exp Ophthalmol. 2011;39:766–70. doi: 10.1111/j.1442-9071.2011.02559.x
12. Ekström C. New cases of primary open angle glaucoma with visual field defects in Northern Uppland, Sweden. Transactions of the Swedish Ophthalmological Society 1983. Ed.: Hedin A, Meeting in Hudiksvall, 15–16 September 1983. Acta Ophthalmol. 1985;63:471.
13. Ekström C. Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey. Acta Ophthalmol Scand. 1996;74:107–12. doi: 10.1111/j.1600-0420.1996.tb00052.x
14. Ekström C, Hårleman K. Risk factors for incident open-angle glaucoma in clinical practise in Sweden: a population-based case−control study. Acta Ophthalmol. 2023;101:530–35. doi: 10.1111/aos.15644
15. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86:238–42. doi: 10.1136/bjo.86.2.238
16. Ekström C, Haglund B. Chronic open-angle glaucoma and advanced visual field defects in a defined population. Acta Ophthalmol. 1991;69:574–80. doi: 10.1111/j.1755-3768.1991.tb04842.x
17. World Health Organisation (WHO). International classification of diseases and related health problems, Tenth Revision (ICD 10). 5th ed. Geneva: World Health Organization, 2015, pp. 401–4.
18. Greenland S, Rothman KJ. Measures of occurrence. In: Rothman KJ, Greenland S, Lash TL, eds. Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Williams; 2008, p. 43–4.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Why Kaplan-Meier fails and cumulative incidence succeeds when calculating probabilities in the presence of competing events. In: Crowley J, ed. Handbook of statistics in clinical oncology. New York: Marcel Dekker, Inc.; 2001, p. 513–23.
20. Heijl A, Aspberg J, Bengtsson B. The effect of different criteria on the number of patients blind from open-angle glaucoma. BMC Ophthalmol. 2011;11:31. doi: 10.1186/1471-2415-11-31
21. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol. 2014;92:421–5. doi: 10.1111/aos.12203
22. Zhao D, Cho J, Kim MH, Friedman DS, Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2015;122:72–8. doi: 10.1016/j.ophtha.2014.07.051
23. Grødum K, Heijl A, Bengtsson B. A comparison of glaucoma patients identified through mass screening and in routine clinical practise. Acta Ophthalmol Scand. 2002;80:627–31. doi: 10.1034/j.1600-0420.2002.800613.x
24. Aspberg J, Heijl A, Bengtsson B. Screening for open-angle glaucoma and its effect on blindness. Am J Ophthalmol. 2021;228:106–16. doi: 10.1016/j.ajo.2021.03.030
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
